


Stabilis



Ceftazidime Avibactam



Tradename

Avycaz	United States of America
Torgena	Brazil
Zavicefta	Argentina, Australia, Belgium, Chile, Finland, France, Germany, Great Britain, Hungary, Ireland, Italy, Luxembourg, Mexico, Norway, Peru, Romania, Slovenia, Spain, Sweden, Switzerland, Tunisia, United States of America



Stability in solutions

		125/31,25 mg/ml	20-25°C		24			4634
		25/6,25 mg/ml	37°C		12			4634
		8/2 >> 40/10 mg/ml	2-8°C		24			2902
		8/2 >> 40/10 mg/ml	25°C		12			2902
	RL	8/2 >> 40/10 mg/ml	2-8°C		24			2902
	RL	8/2 >> 40/10 mg/ml	25°C		12			2902



Compatibility

	Ceftazidime Avibactam Amikacin sulfate	3549
	Ceftazidime Avibactam : 8,25 & 50 mg/ml Aztreonam : 10 & 20 mg/ml	4548
	Ceftazidime Avibactam : 40 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL	4528
	Ceftazidime Avibactam : 40/10 mg/ml Eravacycline : 0,6 mg/ml	4434
	Ceftazidime Avibactam Erythromycin lactobionate	3674

		Ceftazidime Avibactam : 40/10 mg/ml Fosfomycin : 30 mg/ml		4055
		Ceftazidime Avibactam Gentamicin sulfate		3520
		Ceftazidime Avibactam Gentamicin sulfate		3643
		Ceftazidime Avibactam : 40/10 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Ceftazidime Avibactam : 40/10 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Ceftazidime Avibactam : 8 mg/ml Vancomycin hydrochloride : 5 mg/ml		3984
		Ceftazidime Avibactam : 8 & 20 mg/ml Vancomycin hydrochloride : 10 mg/ml		3984
		Ceftazidime Avibactam : 8 >> 40 mg/ml Vancomycin hydrochloride : 15 mg/ml		3984
		Ceftazidime Avibactam : 40 mg/ml Vancomycin hydrochloride : 10 mg/ml		3984
		Ceftazidime Avibactam : 20 & 40 mg/ml Vancomycin hydrochloride : 5 mg/ml		3984



Route of administration






































References

	Type	Publication
2902	Manufacturer	Ceftazidime - avibactam (Avycaz®) - Summary of Product Characteristics Forrest Pharmaceuticals 2015
3520	Manufacturer	Cidomycin - Summary of product Characteristics. Sanofi 2011
3549	Manufacturer	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3643	Manufacturer	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Manufacturer	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3984	Journal	Meyer K, Santarossa M, Danziger L.H, Wenzler E. Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water. Hosp Pharm 2017 ;52;3 : 221-228
4055	Journal	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Journal	Asempta T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056

4434	Journal	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4528	Journal	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4548	Journal	O'Donnell J.N, Xu A, Lodise T.P. Intravenous Compatibility of Ceftazidime/Avibactam and Aztreonam Using Simulated and Actual Y-site Administration. Clin Ther 2020 ; 42, 8: 1580-1586.
4634	Journal	Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics 2022 ;11,4: 458
4801	Journal	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:



Dictionary

 Antibiotic	 Injection
 Tradename	 Stability in solutions
 Container	 Molecule
 Concentration	 Temperature
 Storage	 Duration of stability
 Biosimilar	 Conflicting data
 References	 Polypropylen Syringe
 NaCl 0,9% or Glucose 5%	 Light
 Hour	 Polyisoprene elastomer
 Sodium chloride 0,9%	 Protect from light
 Not specified	 Not specified
RL Ringer's lactate solution	 Compatibility
 Compound	 Solvent
 Chemical instability	 Incompatible
 Compatible	 Unspecified incompatibility
 Immediate precipitation	 Glucose 5%
 Route of administration	 Intravenous infusion
 References	 Dictionary